A sterile line of Aedes aegypti is developed to fight off arbovirosis

August 8, 2018, FAPESP
Margareth Capurro, Professor at the University of São Paulo's Biomedical Science Institute (ICB-USP). Credit: Agência FAPESP

Transgenic males of Aedes aegypti with defective sperm have been created at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil and may be produced on a pilot scale next year. Alongside the development of vaccines, the production of genetically modified mosquitoes could become one of the most effective means of combating epidemics of dengue, chikungunya, Zika and yellow fever.

"These GM males mate with wild females wherever they can, including places that aren't accessible to human action. Owing to the defect introduced into their sperm, the eggs that result from their mating are nonviable, and this helps reduce the population of A. aegypti," said Margareth Capurro, a professor at ICB-USP and principal investigator for the project based on the use of transgenic mosquito lines.

The development of the GM mosquito was funded by the São Paulo Research Foundation—FAPESP and the International Atomic Energy Agency (IAEA, the United Nations' nuclear watchdog).

"So instead of being appropriated by some private-sector company with a profit motive, it should be distributed free of charge by the U.N. to the 44 countries involved in mosquito control. I've also argued that it shouldn't be patented. The technology should be donated to any country that wants to use it."

Capurro stressed that this should not be the only strategy deployed to combat the diseases in question. It should be one of a battery of coordinated control measures ranging from education of the public to the development of vaccines, the use of larvicides and insecticides, and the adequate treatment of breeding grounds such as garbage dumps, tires and other water containers.

According to the FAPESP-supported researcher, Phase 1 of the project was completed with production of the mosquito in ICB-USP's laboratories.

"Next summer, we embark on Phase 2, consisting of field cage tests. The will be confined in large cages with an area of 3 square meters immersed in a natural environment. The aim is to find out whether they can survive and mate in the presence of wind and rain. This is an important test, as genetic modification can induce undesirable traits as well as the traits of interest," said Capurro, who leads the research project.

Phase 2 will be conducted at Moscamed Brasil's biofactory in Juazeiro, Bahia State. This partner institution is a nonprofit established under the aegis of the IAEA's program to develop sterile strains of the Mediterranean fruit fly. The program has already inspired the creation of several biofactories to produce transgenic insects around the world.

Pilot-scale production

The mosquito's life cycle lasts 30 days. Phase 2 will involve the breeding of several generations and the evaluation of each one, so it will take six to eight months, approximately from September 2018 to March or April 2019. If all goes well, Phase 3 should begin in late 2019 or early 2020, seeing pilot-scale production of some 500,000 GM mosquitoes per week.

In this phase, a number of adjustments may be made to the product. The next step will be large-scale implementation of the strategy. To this end, the Juazeiro biofactory already has the installed capacity to produce 14 million GM mosquitoes per week.

"But production at Juazeiro or elsewhere depends on several logistical conditions, such as production cost, transportation cost, hiring and training qualified personnel, and so on," said Capurro. "I intend to deliver the technology ready for use to the Health Ministry and other ministries. They can set up a program to implement it if they see fit. The product will also be delivered to the U.N., so even if Brazil decides not to implement a program, other countries can do so."

Explore further: Transgenic mosquito works to control dengue-carrying mosquitos

Related Stories

Transgenic mosquito works to control dengue-carrying mosquitos

July 7, 2015
Releases of the genetically engineered Oxitec mosquito, commonly known as 'Friendly Aedes aegypti', reduced the dengue mosquito population in an area of Juazeiro, Brazil by 95%, well below the modelled threshold for epidemic ...

Sterilised mosquito trial slashes dengue-spreading population

July 10, 2018
More than 80 percent of a dengue fever-spreading mosquito has been wiped out in an Australian town during a landmark trial scientists said Tuesday offered hope for combating the dangerous pest globally.

Brazil to breed GM mosquitoes to combat dengue

July 10, 2012
Brazil said Monday it will breed huge numbers of genetically modified mosquitoes to help stop the spread of dengue fever, an illness that has already struck nearly 500,000 people this year nationwide.

First Chikungunya-infected Aedes aegypti mosquitos found in Brazil

June 22, 2017
While more than 13,000 cases of Chikungunya viral disease were reported in Brazil in 2015, scientists had never before detected the virus in a captured mosquito in this country. Now, researchers reporting in PLOS Neglected ...

Millions of infected Brazilian mosquitoes to tackle dengue

August 30, 2017
Brazilian scientists on Tuesday began to unleash the first of millions of mosquitoes infected with a bacteria meant to prevent the insects from transmitting the dengue virus to humans.

Recommended for you

New hope for cystic fibrosis

October 19, 2018
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis.

Bug guts shed light on Central America Chagas disease

October 18, 2018
In Central America, Chagas disease, or American trypanosomiasis, is spread by the "kissing bug" Triatoma dimidiata. By collecting DNA from the guts of these bugs, researchers reporting in PLOS Neglected Tropical Diseases ...

Rapid genomic sequencing of Lassa virus in Nigeria enabled real-time response to 2018 outbreak

October 18, 2018
Mounting a collaborative, real-time response to a Lassa fever outbreak in early 2018, doctors and scientists in Nigeria teamed up with researchers at Broad Institute of MIT and Harvard and colleagues to rapidly sequence the ...

Researchers cure drug-resistant infections without antibiotics

October 17, 2018
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria ...

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

How drug resistant TB evolved and spread globally

October 17, 2018
The most common form of Mycobacterium tuberculosis (TB) originated in Europe and spread to Asia, Africa and the Americas with European explorers and colonialists, reveals a new study led by UCL and the Norwegian Institute ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.